{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:13:15Z","timestamp":1762528395048,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40256-025-00752-x","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:12:04Z","timestamp":1754061124000},"page":"829-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5880-9646","authenticated-orcid":false,"given":"Noel","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-835X","authenticated-orcid":false,"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-1962","authenticated-orcid":false,"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-4203","authenticated-orcid":false,"given":"Amrut V.","family":"Ambardekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-2963","authenticated-orcid":false,"given":"Keyur B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Hennum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Marwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pruthviraj","family":"Shivanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3880-6209","authenticated-orcid":false,"given":"Suresh","family":"Siddhanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8892-4488","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Tamby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-215X","authenticated-orcid":false,"given":"Heather","family":"Falvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-777X","authenticated-orcid":false,"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"752_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.863179","volume":"9","author":"B Irabor","year":"2022","unstructured":"Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med. 2022;9:863179.","journal-title":"Front Cardiovasc Med."},{"issue":"22","key":"752_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"752_CR3","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ejhf.2658","volume":"24","author":"A Maestro-Benedicto","year":"2022","unstructured":"Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(12):2367\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"752_CR4","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7\u201322.","journal-title":"Circulation"},{"issue":"9","key":"752_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331(9):778\u201391.","journal-title":"JAMA"},{"issue":"14","key":"752_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2217\/cer-2022-0074","volume":"11","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Fine NM, Ortiz-Perez JT, Brown D, Vera-Llonch M, Reddy SR, et al. Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis. J Comp Eff Res. 2022;11(14):1031\u201344.","journal-title":"J Comp Eff Res."},{"issue":"2","key":"752_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"key":"752_CR8","unstructured":"BridgeBio Pharma. Attruby (acoramidis) [package insert]. 2024 [cited December 11, 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf."},{"key":"752_CR9","unstructured":"BridgeBio Pharma. Beyonttra\u2122 (acoramidis), the first near-complete TTR stabilizer (\u226590%), approved in Japan to treat ATTR-CM. 2025 [cited May 28, 2025] Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-in-japan-to-treat-attr-cm-03-27-2025\/default.aspx."},{"key":"752_CR10","unstructured":"BridgeBio Pharma. Beyonttra\u2122 (acoramidis), the first near complete TTR stabilizer (\u226590%), approved by the European Commission to treat ATTR-CM. 2025 [cited May 28, 2025] Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-by-the-european-commission-to-treat-attr-cm-02-11-2025\/default.aspx."},{"key":"752_CR11","unstructured":"BridgeBio Pharma. Beyonttra\u00ae (acoramidis), the first near-complete TTR stabilizer (\u226590%), approved by the UK Medicines and Healthcare products Regulatory Agency to treat ATTR-CM. 2025 [cited May 28, 2025] Available from: https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/BEYONTTRA-acoramidis-the-First-Near-complete-TTR-Stabilizer-90-Approved-by-the-UK-Medicines-and-Healthcare-Products-Regulatory-Agency-to-Treat-ATTR-CM\/default.aspx."},{"key":"752_CR12","unstructured":"Judge DP, Francesco Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, et al. Acoramidis improves clinical outcomes in transthyretin amyloid cardiomyopathy. Presented at the 2023 American Heart Association Scientific Sessions; November 10\u201313, 2023; Philadelphia, PA, USA."},{"issue":"7624","key":"752_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"1","key":"752_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","volume":"20","author":"D Delgado","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D, et al. Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis. 2025;20(1):29.","journal-title":"Orphanet J Rare Dis"},{"issue":"31","key":"752_CR15","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893\u2013907.","journal-title":"Eur Heart J"},{"key":"752_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","volume":"123","author":"A Porcari","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN. Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. 2024;123:29\u201336.","journal-title":"Eur J Intern Med"},{"key":"752_CR17","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) [package insert]. 2022 [cited January 21, 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204629s033lbl.pdf."},{"key":"752_CR18","unstructured":"Janssen Pharmaceuticals, Inc. Invokana (canagliflozin) [package insert]. 2024 [cited January 21, 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204042s043lbl.pdf."},{"key":"752_CR19","unstructured":"AstraZeneca Pharmaceuticals LP. Farxiga (dapagliflozin) [package insert]. 2023 [cited January 21, 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202293s026lbl.pdf."},{"issue":"24","key":"752_CR20","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"752_CR21","doi-asserted-by":"crossref","unstructured":"Lauppe RE, Liseth Hansen J, Gerdeskold C, Rozenbaum MH, Strand AM, Vakevainen M, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8(2):e001755.","DOI":"10.1136\/openhrt-2021-001755"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00752-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:08:13Z","timestamp":1762528093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00752-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00752-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"4 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by BridgeBio Pharma, Inc., San Francisco, CA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N.D. is a consultant and advisor for Alexion and AstraZeneca; and a speaker for Alnylam. S.H.P. is a consultant and has received fees from BridgeBio, Pfizer, and AstraZeneca; and research support from Novo Nordisk. M.E. and A.V.A. have no relevant financial relationships to disclose. K.B.S. is a consultant, advisor, and speaker for Pfizer. L.H., S.S., J.F.T., and H.F. are employees and stakeholders of BridgeBio Pharma, Inc., San Francisco, CA, USA. R.M., M.A., and P.S. are employees of Definitive Healthcare. J.L.G. is a researcher for Texas Health Resources Clinical Scholarship, Eidos\/BridgeBio, Pfizer, and NHLBI R01HL160892; and a consultant and advisor for Pfizer, Eidos\/BridgeBio, AstraZeneca, Intellia, Tenax Therapeutics, Alnylam, Novo Nordisk, Lumanity, Ultromics, and Alexion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified academic investigators may submit requests for access to aggregated\/summary data that support the findings of this study via MedInfo@BridgeBio.com. Requests for access to study data will be evaluated by\u00a0BridgeBio Pharma, Inc., and access will be provided contingent upon the approval of a research\/study proposal and the execution of a data sharing agreement.\u202fBridgeBio Pharma will consider requests for access to participant-level data if participant privacy is assured through methods such as data deidentification, pseudonymization, or anonymization (as required by applicable law), and if such disclosures were included in the relevant study\u2019s informed consent form or study protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The ATTRibute-CM (NCT03860935) trial was conducted in accordance with the International Council for Harmonization, Good Clinical Practice, and the\u00a0Declaration of Helsinki. The trial was approved by an ethics committee at each participating site.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent to participate in the ATTRibute-CM study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.D. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing. S.H.P. contributed to writing\u2014original draft and writing\u2014review and editing. M.E. contributed to writing\u2014original draft and writing\u2014review and editing. A.V.A. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing. K.B.S. contributed to writing\u2014original draft and writing\u2014review and editing. L.H. and H.F. contributed to the methodology, writing\u2014original draft, and writing\u2014review and editing. S.S. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing. J.F.T. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing. R.M. contributed to writing\u2014original draft and writing\u2014review and editing. M.A. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing. P.S. contributed to writing\u2014original draft and writing\u2014review and editing. J.L.G. contributed to investigation, writing\u2014original draft, and writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}